Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) fundamentals
Glaxosmithkline Pharmaceuticals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as GLAXO (ISIN INE159A01016). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Glaxosmithkline Pharmaceuticals Ltd. does
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Valuation and market data
| Last close | ₹2818.90 |
|---|---|
| Market capitalisation | ₹47,757 crore |
| Enterprise value | ₹46,932 crore |
| P/E (TTM) | 46.10 |
| Price to book | 21.06 |
| Price to sales (TTM) | 6.93 |
| Book value per share | ₹133.84 |
| Dividend yield | 202.21% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Dec 15 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹3,933 crore | ₹1,376 crore | ₹1,012 crore | 59.59 |
| Mar 2025 | ₹3,866 crore | ₹1,248 crore | ₹919 crore | 54.01 |
| Mar 2024 | ₹3,531 crore | ₹809 crore | ₹585 crore | 34.51 |
| Mar 2023 | ₹3,318 crore | ₹832 crore | ₹605 crore | 35.88 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 75.0% |
|---|---|
| Foreign institutions (FII) | 4.8% |
| Mutual funds | 4.9% |
| Other domestic institutions | 2.9% |
| Retail and others | 12.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.